Weston Medical see Intraject flotation:
This article was originally published in Clinica
Weston Medical, a Cambridge, UK-based company, which has developed the Intraject needle-free liquid injector device, is seeking to raise £50 million ($80 million) on the London Stock Exchange. The company has six licence collaborations with drugs companies for use of its injectors. However, at a recent drug delivery conference, the company's CEO Cristopher Samler predicted that companies such as his only had a 10-year window of opportunity before more sophisticated oral drug formulations reduced the need for needle-free drug delivery (see Clinica No 898, p 15).
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.